Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat, wszystkie płci.
- •Dobry ogólny stan zdrowia (skala ECOG: 0 lub 2).
- •Potwierdzony histologicznie rak piersi potrójnie ujemny (ER/PR ≤10%, HER2 ujemny).
- •Pierwotny guz piersi mierzalny ultrasonografią, co najmniej 1 cm.
- •Kwalifikacja do leczenia przedoperacyjnego pembrolizumabem i chemioterapią w celu wyleczenia.
- •Brak wcześniejszego leczenia nowotworu piersi.
- •Gotowość do poddawania się regularnym badaniom ultrasonograficznym, biopsji i pobraniom krwi.
- •Prawidłowe wyniki badań laboratoryjnych (liczba białych krwinek, płytki, hemoglobina, funkcja nerek i wątroby, krzepliwość).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Ellison Institute of Technology (EITM)
Los Angeles, United States
Providence Portland Cancer Institute - Franz Clinic
Portland, United States
Providence St. Vincent Medical Center
Portland, United States
Swedish Cancer Institute
Seattle, United States
Trial contact
Nicole Moxon, RN
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.